Portal de Periódicos da CAPES

miR-34a as part of the resistance network in chronic lymphocytic leukemia

2008; Elsevier BV; Volume: 113; Issue: 16 Linguagem: Inglês

10.1182/blood-2008-08-172254

1528-0020

Thorsten Zenz, Julia Mohr, Eric Eldering, Arnon P. Kater, Andreas Bühler, Dirk Kienle, Dirk Winkler, Jan Dürig, Marinus H. J. van Oers, Daniel Mertens, Hartmut Döhner, Stephan Stilgenbauer,

RNA modifications and cancer

Abstract 17p (TP53) deletion identifies patients with chronic lymphocytic leukemia (CLL) who are resistant to chemotherapy. The members of the miR-34 family have been discovered to be direct p53 targets and mediate some of the p53-dependent effects. We studied miR-34a and miR-34b/c expression in a large cohort to define their potential role in refractory CLL. While no expression of miR-34b/c could be detected, we found variable expression levels of miR-34a. miR-34a levels were up-regulated after DNA damage in the presence of functional p53, but not in cases with 17p deletion (P < .001). We found a strong correlation of low miR-34a levels with impaired DNA damage response, TP53 mutations (without 17p deletion), and fludarabine-refractory disease (also in the absence of 17p deletion). Up-regulation of miR-34a after irradiation was associated with induction of Bax and p21, but not Puma. CLL cells with reduced miR-34a expression showed increased viability after DNA damage independently of 17p status. Therefore, low expression of miR-34a in CLL is associated with p53 inactivation but also chemotherapy-refractory disease, impaired DNA damage response, and apoptosis resistance irrespective of 17p deletion/TP53 mutation. The elucidation of mechanisms underlying miR-34a regulation and overcoming its role in chemotherapy resistance warrant further study.